Warfarin or novel oral anticoagulants for atrial fibrillation?

被引：17

作者：

Larsen, Torben Bjerregaard ^{[1
,2
]}

Lip, Gregory Y. H. ^{[2
,3
]}

机构：

[1] Aalborg Univ Hosp, Aalborg AF Study Grp, Dept Cardiol, DK-9000 Aalborg, Denmark

[2] Aalborg Univ, Fac Hlth, Dept Clin Med, Aalborg Thrombosis Res Unit, Aalborg, Denmark

[3] Univ Birmingham, Ctr Cardiovasc Sci, City Hosp, Birmingham, W Midlands, England

来源：

LANCET | 2014年 / 383卷 / 9921期

关键词：

2012 FOCUSED UPDATE; NATIONWIDE COHORT; ESC GUIDELINES; DABIGATRAN; STROKE; RIVAROXABAN; PREVENTION; MORTALITY; EFFICACY; QUALITY;

D O I：

10.1016/S0140-6736(13)62376-4

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：931 / 933

页数：3

共 11 条

[1] Factors Affecting Quality of Anticoagulation Control Among Patients With Atrial Fibrillation on Warfarin The SAMe-TT2R2 Score [J].

Apostolakis, Stavros ;

Sullivan, Renee M. ;

Olshansky, Brian ;

Lip, Gregory Y. H. .

CHEST, 2013, 144 (05) :1555-1563

[2] Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: A modelling analysis based on a nationwide cohort study [J].

Banerjee, Amitava ;

Lane, Deirdre A. ;

Torp-Pedersen, Christian ;

Lip, Gregory Y. H. .

THROMBOSIS AND HAEMOSTASIS, 2012, 107 (03) :584-589

[3] Predicting the Quality of Anticoagulation During Warfarin Therapy The Basis for an Individualized Approach [J].

Boriani, Giuseppe .

CHEST, 2013, 144 (05) :1437-1438

[4]

Camm AJ, 2012, EUROPACE, V14, P1385, DOI [10.1093/eurheartj/ehs253, 10.1093/europace/eus305]

[5] Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients [J].

Gallagher, Arlene M. ;

Setakis, Efrosini ;

Plumb, Jonathan M. ;

Clemens, Andreas ;

van Staa, Tjeerd-Pieter .

THROMBOSIS AND HAEMOSTASIS, 2011, 106 (05) :968-977

[6] Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillation [J].

Gallego, Pilar ;

Roldan, Vanessa ;

Marin, Francisco ;

Romera, Marta ;

Valdes, Mariano ;

Vicente, Vicente ;

Lip, Gregory Y. H. .

THROMBOSIS AND HAEMOSTASIS, 2013, 110 (06) :1189-1198

[7] Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada Comparative efficacy and cost-effectiveness [J].

Kansal, Anuraag R. ;

Sharma, Michael ;

Bradley-Kennedy, Carole ;

Clemens, Andreas ;

Monz, Brigitta U. ;

Peng, Siyang ;

Roskell, Neil ;

Sorensen, Sonja V. .

THROMBOSIS AND HAEMOSTASIS, 2012, 108 (04) :672-682

[8] Efficacy and Safety of Dabigatran Etexilate and Warfarin in "Real-World" Patients With Atrial Fibrillation A Prospective Nationwide Cohort Study [J].

Larsen, Torben Bjerregaard ;

Rasmussen, Lars Hvilsted ;

Skjoth, Flemming ;

Due, Karen Margrete ;

Callreus, Torbjorn ;

Rosenzweig, Mary ;

Lip, Gregory Y. H. .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2013, 61 (22) :2264-2273

[9] Recommendations for thromboprophylaxis in the 2012 focused update of the ESC guidelines on atrial fibrillation: a commentary [J].

Lip, G. Y. H. .

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2013, 11 (04) :615-626

[10] Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials [J].

Ruff, Christian T. ;

Giugliano, Robert P. ;

Braunwald, Eugene ;

Hoffman, Elaine B. ;

Deenadayalu, Naveen ;

Ezekowitz, Michael D. ;

Camm, A. John ;

Weitz, Jeffrey I. ;

Lewis, Basil S. ;

Parkhomenko, Alexander ;

Yamashita, Takeshi ;

Antman, Elliott M. .

LANCET, 2014, 383 (9921) :955-962

← 1 2 →